Predictive Oncology Partners with Cancer Research Horizons
Saturday, March 18, 2023
Predictive Oncology together with Cancer Research Horizons announce that they have partnered to drive the development of oncology drugs utilising Predictive Oncology’s PEDAL™ platform.
This collaboration with Cancer Research Horizons represents a fundamental shift in drug discovery leading to the accelerated development of cancer therapies using compounds originating from the CRUK network and developed by Cancer Research Horizons in partnership with global network. This potential collaboration will be a win for patients not just in the UK or US, but worldwide.
The collaboration will utilise Predictive Oncology’s PEDAL technology to evaluate Cancer Research Horizons’ pre-clinical drug inhibitors of Glutaminase in order to determine which cancer types and patient populations are most likely to respond to treatment with these compounds. PEDAL is an artificial intelligence and machine learning platform which makes high-confidence drug response predictions enabling a more informed selection of drug-tumour type combinations for clinical development. PEDAL increases the probability of clinical success by efficiently addressing tumour heterogeneity during pre-clinical stages.
